CD8A and neoplasm: To assess the capacity of CCL21 + ICAM1-stimulated CD8+ T-cells to suppress tumor development in vivo, we treated mice bearing B16-ovalbumin tumors with T-cells that were pre-cultured for 7 days on either uncoated substrates, or on substrate-immobilized CCL21 + ICAM1.